AmpliPhi granted Japanese patent covering the use of phage therapy to resensitize Pseudomonas aeruginosa infections to antibiotics
![](/46/pdcnewsitem/04/21/15/ampliphibio.jpg)
AB-PA01 designed to broadly target both CF and non-CF Pseudomonas isolates and potentially eradicate the infection instead of merely keeping it at bay.
AmpliPhi Biosciences has announced that the Japanese Patent Office has granted AmpliPhi a patent for the “Beneficial effects of bacteriophage treatments” targeting Pseudomonas aeruginosa (Pseudomonas) infections. A corresponding patent has been granted in the US and is currently being prosecuted in Canada. Additional patents with broader bacterial species claims have been granted in the European Union and Australia.
The patent covers the treatment of Pseudomonas infections through the sequential use of a bacteriophage (phage) therapeutic followed by an antibiotic to which the bacteria were formerly resistant. During the first stage of phage administration, antibiotic-resistant Pseudomonas are placed under extreme selective pressure by the attacking phage. Following the initial assault, most of the bacteria die, but a small portion may evade the phage attack by mutating in a way that protects them from the phage but at the same time resensitizes that population to antibiotics. Antibiotics are then administered to deplete the remaining bacterial population. This resensitization phenomenon has been observed in both in vitro and in vivo experiments, as well as in a few antibiotic-resistant human infections, including a previously-reported case where an antibiotic-resistant Pseudomonas bladder infection was treated and cleared in Australia under a compassionate use exemption.
Pseudomonas infects almost 60% of cystic fibrosis (CF) patients overall, with approximately 80% of patients over the age of 18 chronically infected by the pathogenic bacteria. Recurrent Pseudomonas infections cause severe lung damage and can lead to bronchiectasis and the need for lung transplants. Current standard of care treatment for CF patients include inhaled antibiotics that tamp down but may not eliminate the infection. AmpliPhi’s investigational drug therapy, AB-PA01, is designed to broadly target both CF and non-CF Pseudomonas isolates and potentially eradicate the infection instead of merely keeping it at bay.
“Through a step-wise treatment paradigm of AB-PA01 followed by antibiotics, we envision a treatment modality that effectively clears chronic Pseudomonas infections in CF patients,” said M. Scott Salka, CEO of AmpliPhi Biosciences. “By resensitizing Pseudomonas to antibiotics, we can turn back the clock on currently ineffective antibiotics and make them relevant again. Antibiotic resensitization has the potential to provide patients and caregivers with a new set of weapons to make impactful progress against the growing threat of antibiotic resistance by combining the natural ability of phage to selectively target bacteria with the current arsenal of antibiotics. We look forward to evaluating our proprietary phage cocktail alongside existing antibiotics to address recurrent and resistant Pseudomonas infections in patients with CF.”
AB-PA01 is currently being manufactured in AmpliPhi’s cGMP facility and is in nonclinical studies at the Royal Brompton Hospital, London, UK. AmpliPhi anticipates initiating a Phase 1 clinical trial in 2017 of AB-PA01 for the treatment of CF using a nebulized formulation of the phage cocktail.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance